S-2-amino-5-(2-nitroimidazol-1-yl)pentanoic acid: A model for potential bioreductively activated prodrugs for inhibitors of nitric oxide synthase (NOS) activity

Anti-Cancer Drug Design

Volumn 12, Issue 1, 1997, Pages 61-65

  Ulhaq, Saraj ^a,b   Naylor, Matthew A ^a,c   Chinje, Edwin C ^a,d   Threadgill, Michael D ^b   Stratford, Ian J ^a,d  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b University of Bath ^*  (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bioreductive; Hypoxia; Nitroimidazole; Prodrug

Indexed keywords

2 AMINO 5 (2 NITROIMIDAZOL 1 YL)PENTANOIC ACID; BRAIN ENZYME; NITRIC OXIDE SYNTHASE INHIBITOR; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION ANALYSIS;

ANIMALS; IMIDAZOLES; MALE; NITRIC OXIDE SYNTHASE; PRODRUGS; RATS; RATS, WISTAR;

EID: 0031023721     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. ADAMS, G.E. & STRATFORD, I.J. (1994). Bioreductive drugs for cancer-therapy - the search for tumour specificity. International Journal of Radiation Oncology, Biology and Physics, 29, 231.
2. ANDRADE, S.P., HART, I.R. & PIPER, PJ. (1992). Inhibitors of nitric oxide selectively reduce flow in tumour-associated neovasculature. British Journal of Pharmacology, 107, 1092.
3. KNOWLES, R.G., MERRETT, M., SALTER,M & MONCADA, S (1990). Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat. Biochemical Journal, 270, 833.
4. MARLETTA, M.A. (1994). Approaches toward selective inhibition of nitric oxide synthase. Journal of Medicinal Chemistry, 37, 1899.
5. McCLELLAND, R.A. (1990). Molecular interactions and biological effects of the products of reduction of nitroimidazoles. In Selective Activation of Drugs by Redox Processes. Adams, G.E, Breccia, A., Fielden, E.M. & Wardman, P. (eds), p. 125. Plenum Publishing Corporation: New York.
6. MONCADA, S., PALMER, R.M J & HIGGS, E.A. (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Reviews, 43, 109.
7. G-Nitro arguinie (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. British Journal of Pharmacology, 99, 408.
8. δ-hydroxy-L-ornithine from L-glutamic acid. Journal of Organic Chemistry, 49, 3527.
9. REES, D.D, PALMER, R.M.J., SCHULTZ, R., HODSON, H.F. & MONCADA, S (1990). Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. British Journal of Pharmacology, 101, 746.
10. 2+-independent nitric oxide synthases. FEBS Letters, 291, 145.
11. SCOBIE, M. & THREADGILL, M.D. (1994). Tumor-targeted boranes. 4. Synthesis of nitroimidazole-carboranes with polyether-isoxazole links, Journal of Organic Chemistry, 59, 7008.
12. 2 tension measurements. Cancer Research, 51, 6098.
13. WALTON, M.I. & WORKMAN, P. (1987). Nitroimidazole bioreductive metabolism-quantitation and characterization of mouse-tissue benzimidazole nitroreductases in vivo and in vitro. Biochemical Pharmacology, 38, 887.
14. WILSON, W.R. (1992). Tumour hypoxia: challenges for cancer chemotherapy. In Cancer Biology and Medicine. Waring, M.J. & Ponder, B.A.J. (eds), p. 87. Kluwer Academic Publishers: Lancaster.
15. WOOD, PJ, STRATFORD, I. J., ADAMS, G. E , SZABO, C., THIEMERMANN, C. & VANE, J.R. (1993). Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochemical and Biophysical Research Communications, 192, 505.
16. G-nitro-L-arginine. Cancer Research, 54, 6458.
17. WORKMAN, P. & STRATFORD, I.J (1993). The experimental development of bioreductive drugs and their role in cancer-therapy. Cancer Metastasis Reviews, 12, 73.